A New Era in Health: WHO Adds Mounjaro and Ozempic to Essential Medicines List

In a groundbreaking move set to revolutionize global health, the World Health Organization (WHO) has officially included two highly effective medications, Mounjaro (tirzepatide) and Ozempic (semaglutide), in its coveted Essential Medicines List (EML). This landmark decision acknowledges the immense potential of these GLP-1 receptor agonists in tackling the escalating challenges of Type 2 diabetes and obesity worldwide, promising enhanced access and better patient outcomes for millions.

The inclusion of these powerful drugs marks a pivotal moment for global public health.

Semaglutide, known by brand names like Ozempic and Wegovy, has been added specifically for Type 2 diabetes, with its anti-obesity formulation, Wegovy, also recommended for weight management under specific conditions. Tirzepatide, marketed as Mounjaro, has been added for Type 2 diabetes, with its role in obesity management currently under evaluation.

These medications are celebrated for their dual action: not only do they effectively control blood sugar levels in diabetic patients, but they also significantly aid in weight loss, addressing two interconnected and growing health crises.

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, underscored the critical importance of this update, stating, “GLP-1 analogues hold immense potential for public health, but are extremely expensive.” Indeed, while the scientific community rejoices at the recognition of these game-changing treatments, a significant hurdle remains: their exorbitant cost.

This high price tag poses a substantial barrier, particularly for low-income countries and vulnerable populations who stand to benefit most.

Recognizing this challenge, the WHO is not merely adding these drugs to the list; it is simultaneously launching a robust call to action. The organization is actively engaging with pharmaceutical companies to negotiate lower prices and is urging countries to explore innovative financing mechanisms, pooled procurement, and local production capabilities to make these life-saving medications more affordable and accessible.

The goal is to ensure that the benefits of Mounjaro and Ozempic are not confined to affluent nations but are distributed equitably across the globe.

This update is part of the 14th edition of the EML and the 9th edition of the EML for children, reflecting a comprehensive approach to global health priorities.

Beyond Mounjaro and Ozempic, the WHO's revised list also features new antibiotics crucial for combating antimicrobial resistance, updated malaria treatments, expanded options for neglected tropical diseases, and a novel treatment for multiple sclerosis. This holistic update reinforces the WHO's commitment to ensuring that essential, effective, and safe medicines are available to everyone, everywhere.

The journey ahead involves navigating the complexities of drug pricing, intellectual property, and supply chain logistics.

Yet, with Mounjaro and Ozempic now formally recognized as essential, the global health community takes a monumental step forward. This decision offers a beacon of hope, promising a future where cutting-edge treatments for diabetes and obesity are within reach for all, fostering healthier communities and saving countless lives.